Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Cell Reports

Volumn 5, Issue 4, 2013, Pages 1047-1059

  Waibel, Michaela ^a   Solomon, Vanessa S ^a   Knight, Deborah A ^a   Ralli, Rachael A ^a   Kim, Sang Kyu ^a   Banks, Kellie Marie ^a   Vidacs, Eva ^a   Virely, Clemence ^b,c,d   Sia, Keith C S ^e   Bracken, Lauryn S ^e   Collins Underwood, Racquel ^f   Drenberg, Christina ^f   Ramsey, Laura B ^f   Meyer, Sara C ^g   Takiguchi, Megumi ^h   Dickins, Ross A ^h   Levine, Ross ^g   Ghysdael, Jacques ^b,c,d   Dawson, Mark A ^i,j   Lock, Richard B ^e   Mullighan, Charles G ^f   Johnstone, Ricky W ^a,k   more..

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b INSTITUT CURIE   (France)

^c CNRS   (France)

^d INSERM U1005   (France)

^e University of New South Wales   (Australia)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL XL; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION PROFILING; HUMAN; LEUKEMIA CELL; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; TRANSCRIPTION REGULATION; TUMOR REGRESSION; UPREGULATION;

MUS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; JANUS KINASE 2; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NITROPHENOLS; PIPERAZINES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84888430616     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.10.038     Document Type: Article

References (42)

1. Atallah E., Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev. Anticancer Ther. 2009, 9:663-670.
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061. Cancer Genome Project.
3. Carron C., Cormier F., Janin A., Lacronique V., Giovannini M., Daniel M.T., Bernard O., Ghysdael J. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000, 95:3891-3899.
4. Cragg M.S., Harris C., Strasser A., Scott C.L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 2009, 9:321-326.
5. Dai C., Chung I.J., Krantz S.B. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp. Hematol. 2005, 33:152-158.
6. Dawson M.A., Bannister A.J., Göttgens B., Foster S.D., Bartke T., Green A.R., Kouzarides T. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009, 461:819-822.
7. Fiskus W., Verstovsek S., Manshouri T., Smith J.E., Peth K., Abhyankar S., McGuirk J., Bhalla K.N. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol. Cancer Ther. 2013, 12:577-588.
8. Ghoreschi K., Laurence A., O'Shea J.J. Janus kinases in immune cell signaling. Immunol. Rev. 2009, 228:273-287.
9. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J., Kang H., Liu W., Dobbin K.K., Smith M.A., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
10. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., Shiloh R., Iacobucci I., Shochat C., Zeligson S., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
11. Ho J.M., Nguyen M.H., Dierov J.K., Badger K.M., Beattie B.K., Tartaro P., Haq R., Zanke B.W., Carroll M.P., Barber D.L. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 2002, 100:1438-1448.
12. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
13. Knight Z.A., Lin H., Shokat K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 2010, 10:130-137.
14. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.X., Sneed T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
15. Koppikar P., Bhagwat N., Kilpivaara O., Manshouri T., Adli M., Hricik T., Liu F., Saunders L.M., Mullally A., Abdel-Wahab O., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.
16. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N.Engl. J. Med. 2005, 352:1779-1790.
17. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffé M., Berthou C., Lessard M., Berger R., Ghysdael J., Bernard O.A. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
18. Lessene G., Czabotar P.E., Sleebs B.E., Zobel K., Lowes K.N., Adams J.M., Baell J.B., Colman P.M., Deshayes K., Fairbrother W.J., et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 2013, 9:390-397.
19. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
20. Marty C., Lacout C., Martin A., Hasan S., Jacquot S., Birling M.C., Vainchenker W., Villeval J.L. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010, 116:783-787.
21. Maude S.L., Tasian S.K., Vincent T., Hall J.W., Sheen C., Roberts K.G., Seif A.E., Barrett D.M., Chen I.M., Collins J.R., et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012, 120:3510-3518.
22. Mérino D., Khaw S.L., Glaser S.P., Anderson D.J., Belmont L.D., Wong C., Yue P., Robati M., Phipson B., Fairlie W.D., et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012, 119:5807-5816.
23. Mullally A., Lane S.W., Ball B., Megerdichian C., Okabe R., Al-Shahrour F., Paktinat M., Haydu J.E., Housman E., Lord A.M., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17:584-596.
24. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., Ma J., Coustan-Smith E., Harvey R.C., Willman C.L., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 2009, 41:1243-1246.
25. Mullighan C.G., Zhang J., Harvey R.C., Collins-Underwood J.R., Schulman B.A., Phillips L.A., Tasian S.K., Loh M.L., Su X., Liu W., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2009, 106:9414-9418.
26. Nguyen M.H., Ho J.M., Beattie B.K., Barber D.L. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway. J.Biol. Chem. 2001, 276:32704-32713.
27. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
28. Pardanani A. Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia 2012, 26:1449-1451.
29. Pardanani A., Hood J., Lasho T., Levine R.L., Martin M.B., Noronha G., Finke C., Mak C.C., Mesa R., Zhu H., et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007, 21:1658-1668.
30. Roberts K.G., Morin R.D., Zhang J., Hirst M., Zhao Y., Su X., Chen S.C., Payne-Turner D., Churchman M.L., Harvey R.C., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
31. Röder S., Steimle C., Meinhardt G., Pahl H.L. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp. Hematol. 2001, 29:694-702.
32. Santos F.P., Verstovsek S. JAK2 inhibitors: are they the solution?. Clin. Lymphoma Myeloma Leuk. 2011, 11(Suppl 1):S28-S36.
33. Sayyah J., Sayeski P.P. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Curr. Oncol. Rep. 2009, 11:117-124.
34. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria R., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998, 17:5321-5333.
35. Silva M., Richard C., Benito A., Sanz C., Olalla I., Fernández-Luna J.L. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N.Engl. J. Med. 1998, 338:564-571.
36. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
37. Stein B.L., Crispino J.D., Moliterno A.R. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr. Opin. Oncol. 2011, 23:609-616.
38. Van Roosbroeck K., Cox L., Tousseyn T., Lahortiga I., Gielen O., Cauwelier B., De Paepe P., Verhoef G., Marynen P., Vandenberghe P., et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011, 117:4056-4064.
39. Weigert O., Lane A.A., Bird L., Kopp N., Chapuy B., van Bodegom D., Toms A.V., Marubayashi S., Christie A.L., McKeown M., et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J.Exp. Med. 2012, 209:259-273.
40. Whitecross K.F., Alsop A.E., Cluse L.A., Wiegmans A., Banks K.M., Coomans C., Peart M.J., Newbold A., Lindemann R.K., Johnstone R.W. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009, 113:1982-1991.
41. Will B., Siddiqi T., Jordà M.A., Shimamura T., Luptakova K., Staber P.B., Costa D.B., Steidl U., Tenen D.G., Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood 2010, 115:2901-2909.
42. Zeuner A., Pedini F., Francescangeli F., Signore M., Girelli G., Tafuri A., De Maria R. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood 2009, 113:1522-1525.